Teva flunks orphan drug test with CRL on Auspex-developed chorea treatment

Another billion-dollar-plus deal failed to play out as planned as the FDA dealt Teva Pharmaceutical Industries Ltd. a CRL on its NDA for SD-809 to treat chorea – involuntary writhing movements – associated with Huntington disease.